Eledon announces positive topline results from phase 2a trial of tegoprubart demonstrating safety, target engagement, and biomarker response in patients living with amyotrophic lateral sclerosis

Irvine, calif., may 31, 2022 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced topline results from a phase 2a clinical trial of tegoprubart (formerly at-1501) in patients with amyotrophic lateral sclerosis (als).1
ELDN Ratings Summary
ELDN Quant Ranking